癌症（英文版）2017，Vol.36Issue(11)：574-582,9.DOI:10.1186/s40880-017-0230-7
Comparison of efficacy, safety,
and quality of life between sorafenib
and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
Comparison of efficacy, safety,
and quality of life between sorafenib
and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
Wen Cai 1Wen Kong 1Baijun Dong 1Jin Zhang 1Yonghui Chen 1Wei Xue 1Yiran Huang 1Lixin Zhou 2Jiwei Huang2
作者信息
- 1. Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200123, P. R. China
- 2. Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Rd., Pudong District, Shanghai 200127, P. R. China
- 折叠
摘要
关键词
Metastatic renal cell carcinoma/Sorafenib/Sunitinib/Quality of lifeKey words
Metastatic renal cell carcinoma/Sorafenib/Sunitinib/Quality of life引用本文复制引用
Wen Cai,Wen Kong,Baijun Dong,Jin Zhang,Yonghui Chen,Wei Xue,Yiran Huang,Lixin Zhou,Jiwei Huang..Comparison of efficacy, safety,
and quality of life between sorafenib
and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma[J].癌症（英文版）,2017,36(11):574-582,9.
